Lab Glassware Division 中文(Chinese)

A Simple HPLC Method for the Simultaneous Determination of Five Proposed Medicines for COVID-19 with Diamonsil® Plus C18 Column

Method: HPLC
Matrix: Medicine
Application No.: 101929
Componds: Favipiravir, Molnupiravir, Remdesivir, Ritonavir, Ivermectin
Columns: Diamonsil® Plus C18 5μm 150 x 4.6 mm
Cat No.: 99401
Sample Pretreatment: Standards: Individual stock solutions were prepared in methanol at a concentration of 1.0 mg/mL. A working solution of the mixture of all 5 drugs was obtained by dilution of the stock solution with methanol/water (3/7). All stock solutions should be stored at -20 ℃. Working solutions are prepared when needed and used out as soon as possible.
Conditions: Mobile Phase:
A: 0.1% phosphoric acid in water (v/v); B: Acetonitrile: Methanol = 4 / 6
Gradient: hold 30% B for 0.5 min, 30 to 98% B in 4.5 min, hold 98% B for 5 min,
98 to 30% B in 1 min, equilibrate at 30% B for 4 min.
Flow Rate: 1.0 mL/min;
Injection: 10 µL;
Temperature: 30 ℃;
Wavelength: 240nm
Publisher: Dikma Technologies Inc.
Keyword: Favipiravir, Molnupiravir, Remdesivir, Ritonavir, Ivermectin, HPLC, Diamonsil Plus C18, COVID-19
Abstract: In this application note, a simple HPLC-UV method is developed for simultaneous analysis of ivermectin, molnupiravir, remdesivir, favipiravir and ritonavir.

 

No.

Compounds

Concentration (µg/mL)

Retention Time(min)

Resolution

Asymmetry

1

Favipiravir

45

2.69

-

1.10

2

Molnupiravir

45

3.65

8.37

1.08

3

Remdesivir

10

6.60

27.7

1.08

4

Ritonavir

65

7.24

6.83

1.07

5

Ivermectin

45

9.21

17.6

1.06